Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Sees Cervarix Cross-Protection, Age Range As Key Points Of Differentiation

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

GlaxoSmithKline expects to highlight a broad age range and cross-protection against multiple viral strains to differentiate its human papilloma virus vaccine Cervarix from Merck’s competing vaccine Gardasil.

You may also be interested in...



GSK Wagers On Cervarix In Head-To-Head Trial Against Merck’s Gardasil

GlaxoSmithKline raised the stakes behind its anticipated launch of the investigational cervical cancer vaccine Cervarix Jan. 18, announcing the initiation of the first head-to-head trial comparing it to Merck's Gardasil. The study will evaluate differences between the two vaccines in inducing strong and sustained immune responses to the human papilloma virus in women

Merck Gardasil BLA a priority?

Merck is requesting a priority review for its human papillomavirus vaccine Gardasil (quadrivalent human papillomavirus types 6, 11, 16, 18, recombinant), submitted Dec. 1. If granted a priority review, a June 1, 2006 approval would allow Merck to launch the vaccine before the 2006 back-to-school immunization season. GlaxoSmithKline continues development of its HPV vaccine Cervarix, which it claims offers viral protection against multiple viral strains and in a wider age group than Gardasil (Pharmaceutical Approvals Monthly July 2005, p. 4). GSK said it plans to submit Cervarix in 2006...

Merck Gardasil BLA a priority?

Merck is requesting a priority review for its human papillomavirus vaccine Gardasil (quadrivalent human papillomavirus types 6, 11, 16, 18, recombinant), submitted Dec. 1. If granted a priority review, a June 1, 2006 approval would allow Merck to launch the vaccine before the 2006 back-to-school immunization season. GlaxoSmithKline continues development of its HPV vaccine Cervarix, which it claims offers viral protection against multiple viral strains and in a wider age group than Gardasil (Pharmaceutical Approvals Monthly July 2005, p. 4). GSK said it plans to submit Cervarix in 2006...

Related Content

Topics

UsernamePublicRestriction

Register

PS017586

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel